OBJECTIVE: To compare the long-term prognostic significance of different definitions of immunologic and virologic responses to highly active antiretroviral therapy (HAART) at 6 months. METHODS: This was a prospective study conducted in 68 French hospitals. HAART was initiated in 2236 protease inhibitor-naive patients included in the French Hospital Database on HIV. Multivariate Cox proportional hazard models measuring time from 6 months after starting HAART were used to compare the strength of the association between different definitions of immunologic and virologic responses at 6 months and subsequent progression to AIDS or death. The Akaike's Information Criteria were used to identify the most appropriate model. RESULTS: During a median follow-up of 58 months, 325 patients experienced an AIDS-defining event or died. The model that fitted best was the model in which the CD4 cell count and plasma HIV-1 RNA values attained at 6 months were considered. The risk of clinical progression at 5 years ranged from 7% (95% confidence interval [CI]: 4-10) in patients whose CD4 cell count at 6 months was >or=350 cells/microL and whose HIV-1 RNA concentration was <3 log10 copies/mL to 63% (95% CI: 52-75) in patients whose CD4 cell count at 6 months was <100 cells/microL and whose HIV-1 RNA concentration was >or=5 log10. CONCLUSIONS: Plasma HIV-1 RNA concentration and CD4 cell count should be taken into account independently when evaluating early response to treatment. The persistent impact of early response on clinical progression at 5 years emphasizes the major importance of the success of first-line HAART.
OBJECTIVE: To compare the long-term prognostic significance of different definitions of immunologic and virologic responses to highly active antiretroviral therapy (HAART) at 6 months. METHODS: This was a prospective study conducted in 68 French hospitals. HAART was initiated in 2236 protease inhibitor-naive patients included in the French Hospital Database on HIV. Multivariate Cox proportional hazard models measuring time from 6 months after starting HAART were used to compare the strength of the association between different definitions of immunologic and virologic responses at 6 months and subsequent progression to AIDS or death. The Akaike's Information Criteria were used to identify the most appropriate model. RESULTS: During a median follow-up of 58 months, 325 patients experienced an AIDS-defining event or died. The model that fitted best was the model in which the CD4 cell count and plasma HIV-1 RNA values attained at 6 months were considered. The risk of clinical progression at 5 years ranged from 7% (95% confidence interval [CI]: 4-10) in patients whose CD4 cell count at 6 months was >or=350 cells/microL and whose HIV-1 RNA concentration was <3 log10 copies/mL to 63% (95% CI: 52-75) in patients whose CD4 cell count at 6 months was <100 cells/microL and whose HIV-1 RNA concentration was >or=5 log10. CONCLUSIONS: Plasma HIV-1 RNA concentration and CD4 cell count should be taken into account independently when evaluating early response to treatment. The persistent impact of early response on clinical progression at 5 years emphasizes the major importance of the success of first-line HAART.
Authors: Emilie Lanoy; Margaret May; Amanda Mocroft; Andrew Phillip; Amy Justice; Geneviève Chêne; Hansjakob Furrer; Timothy Sterling; Antonella D'Arminio Monforte; Lluís Force; John Gill; Ross Harris; Robert S Hogg; Jürgen Rockstroh; Mike Saag; Pavel Khaykin; Frank de Wolf; Jonathan A C Sterne; Dominique Costagliola Journal: AIDS Date: 2009-10-23 Impact factor: 4.177
Authors: Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan Journal: Nat Med Date: 2008-03-30 Impact factor: 53.440
Authors: Suely Hiromi Tuboi; Antonio Guilherme Pacheco; Lee H Harrison; Roslyn A Stone; Margaret May; Martin W G Brinkhof; François Dabis; Matthias Egger; Denis Nash; David Bangsberg; Paula Braitstein; Constantin T Yiannoutsos; Robin Wood; Eduardo Sprinz; Mauro Schechter Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: David Morquin; Vincent Le Moing; Thibaut Mura; Alain Makinson; Kada Klouche; Olivier Jonquet; Jacques Reynes; Philippe Corne Journal: Ann Intensive Care Date: 2012-07-04 Impact factor: 6.925
Authors: Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie Journal: PLoS One Date: 2010-09-09 Impact factor: 3.240
Authors: Félix Gutierrez; Sergio Padilla; Mar Masiá; José A Iribarren; Santiago Moreno; Pompeyo Viciana; Leopoldo Muñoz; José L Gómez Sirvent; Francesc Vidal; José López-Aldeguer; José R Blanco; Manuel Leal; María Angeles Rodríguez-Arenas; Santiago Perez Hoyos Journal: PLoS One Date: 2006-12-20 Impact factor: 3.240
Authors: Alexander Billioux; Gertrude Nakigozi; Kevin Newell; Larry W Chang; Thomas C Quinn; Ron H Gray; Anthony Ndyanabo; Ronald Galiwango; Valerian Kiggundu; David Serwadda; Steven J Reynolds Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240